60 related articles for article (PubMed ID: 8811329)
1. CD5+ B cells in Graves' disease: correlation with disease activity.
Corrales JJ; Orfao A; López A; Mories MT; Miralles JM; Ciudad J
Horm Metab Res; 1996 Jun; 28(6):280-5. PubMed ID: 8811329
[TBL] [Abstract][Full Text] [Related]
2. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
3. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
[TBL] [Abstract][Full Text] [Related]
4. Production of IL-10 and IL-12 in CD40 and interleukin 4-activated mononuclear cells from patients with Graves' disease.
Itoh M; Uchimura K; Makino M; Kobayashi T; Hayashi R; Nagata M; Kakizawa H; Fujiwara K; Nagasaka A
Cytokine; 2000 Jun; 12(6):688-93. PubMed ID: 10843746
[TBL] [Abstract][Full Text] [Related]
5. Serial analysis of the effects of methimazole therapy on circulating B cell subsets in Graves' disease.
Corrales JJ; Orfao A; López A; Ciudad J; Mories MT
J Endocrinol; 1996 Nov; 151(2):231-40. PubMed ID: 8958783
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
7. Generation of a transgenic animal model of hyperthyroid Graves' disease.
Kim-Saijo M; Akamizu T; Ikuta K; Iida Y; Ohmori K; Matsubara K; Matsuda Y; Suzuki M; Matsuda F; Nakao K
Eur J Immunol; 2003 Sep; 33(9):2531-8. PubMed ID: 12938229
[TBL] [Abstract][Full Text] [Related]
8. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
9. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
10. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
Balázs C; Kiss E
Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729
[TBL] [Abstract][Full Text] [Related]
11. Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves disease: relationship with disease activity.
Corrales JJ; Orfao A; López A; Mories MT; Miralles JM; Ciudad J
Cytometry; 1997 Jun; 30(3):118-23. PubMed ID: 9222097
[TBL] [Abstract][Full Text] [Related]
12. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
[TBL] [Abstract][Full Text] [Related]
13. Increase of peripheral B lymphocytes in Graves' disease.
Mori H; Amino N; Iwatani Y; Kabutomori O; Asari S; Motoi S; Miyai K; Kumahara Y
Clin Exp Immunol; 1980 Oct; 42(1):33-40. PubMed ID: 6970099
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balázs C; Farid NR
Acta Med Hung; 1991; 48(1-2):3-11. PubMed ID: 1813855
[TBL] [Abstract][Full Text] [Related]
15. Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease.
Aust G; Lehmann I; Heberling HJ
Exp Clin Endocrinol Diabetes; 1996; 104(1):50-8. PubMed ID: 8750571
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
Karlsson FA; Tötterman TH
Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
[TBL] [Abstract][Full Text] [Related]
17. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them.
Böhm I
Biomed Pharmacother; 2004 Jun; 58(5):338-43. PubMed ID: 15194170
[TBL] [Abstract][Full Text] [Related]
18. Marked increase of CD5 + B cells in hyperthyroid Graves' disease.
Iwatani Y; Amino N; Kaneda T; Ichihara K; Tamaki H; Tachi J; Matsuzuka F; Fukata S; Kuma K; Miyai K
Clin Exp Immunol; 1989 Nov; 78(2):196-200. PubMed ID: 12412748
[TBL] [Abstract][Full Text] [Related]
19. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
20. Production of and response to interleukin-2 in Graves' disease.
Eisenstein Z; Engelsman E; Weiss M; Kalechman Y; Sredni B
J Clin Immunol; 1988 Sep; 8(5):349-55. PubMed ID: 2972741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
